Results From the Phase 3 ElevAATe Clinical Trial in Alpha-1 Antitrypsin Deficiency by Madaline Spencer| Published on: Jun 19, 2026

Results From the Phase 3 ElevAATe Clinical Trial in Alpha-1 Antitrypsin Deficiency by Madaline Spencer| Published on: Jun 19, 2026 Alaa Hamed, MD, Global Head of Medical Affairs Rare Diseases at Sanofi, discusses results from the phase 2 ElevAATe clinical trial of efdoralprin alfa in patients with alpha-1 antitrypsin deficiency (AATD). https://checkrare.com/results-from-the-phase-3-elevaate-clinical-trial-in-alpha-1-antitrypsin-deficiency/

Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks by Madaline Spencer| Published on: Jun 25, 2026

https://checkrare.com/oral-deucrictibant-for-on-demand-treatment-of-hereditary-angioedema-attacks/ A study published in The Lancet Hematology evaluated the efficacy and safety of deucrictibant for the on-demand treatment of hereditary angioedema (HAE) attacks. Hereditary angioedema (HAE) is a rare condition characterized by recurrent episodes of severe swelling of the skin and mucous membranes. These attacks generally become more frequent after puberty, and continue throughout life, often affecting the skin, gastrointestinal tract, and upper airway. Triggers for these episodic HAE attacks vary but may include emotional and physical stressors, including dental procedures. HAE may be caused by genetic changes in the SERPING1 gene (also called the C1NH gene) or in the F12 gene. In some cases, the genetic cause is not yet certain.

Effects of a SGLT2 inhibitor on Reducing Heart Failure in Carriers of Cardiomyopathy-Associated Genetic Variants by Madaline Spencer| Published on: Jun 24, 2026

Effects of a SGLT2 inhibitor on Reducing Heart Failure in Carriers of Cardiomyopathy-Associated Genetic Variants by Madaline Spencer| Published on: Jun 24, 2026 https://checkrare.com/effects-of-a-sglt2-inhibitor-on-reducing-heart-failure-in-carriers-of-cardiomyopathy-associated-genetic-variants/

Results From the VISIONARY Clinical Trial of Sibeprenlimab in Patients With IgA Nephropathy by Madaline Spencer| Published on: Jun 29, 2026

Results From the VISIONARY Clinical Trial of Sibeprenlimab in Patients With IgA Nephropathy by Madaline Spencer| Published on: Jun 29, 2026 https://checkrare.com/results-from-the-visionary-clinical-trial-of-sibeprenlimab-in-patients-with-iga-nephropathy/

Advancing Clinical Excellence IMPACT CLL & MCL: IMPlementing Advances in Cancer Treatment for Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Advancing Clinical Excellence IMPACT CLL & MCL: IMPlementing Advances in Cancer Treatment for Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Welcome to our educational platform, where Medscape Oncology Global provides high-quality education specifically designed for hematologists/oncologists and members of the multidisciplinary team to identify and address the key barriers to effective patient care in... https://www.medscape.org/advances/impact-cll-mcl-2025a1000ar6?src=mkmcmr_driv_32025_mscpedu_436318.01_ace_launch&uac=148436CN

New Guidance on the Pharmacologic Treatment of Obesity Neil Skolnik, MD

https://www.medscape.com/viewarticle/new-guidance-pharmacologic-treatment-obesity-2026a1000k57?ecd=wnl_tp10_daily_260625_MSCPEDIT_etid8453308&uac=148436CN&impID=8453308

Managing Myeloproliferative Neoplasms: Practice Your Skills in These Virtual Patient Simulations Authors: Claire N. Harrison, DM, FRCP, FRCPath; Haifa Kathrin Al-Ali, MD

https://www.medscape.org/viewarticle/managing-myeloproliferative-neoplasms-practice-your-skills-2026a1000f5o?page=1&src=mkmcmr_driv_psims_mscpedu_260627-OUS-HONC-managing-myeloproliferative-neoplasms-practice-your-skills-2026a1000f5o-cta&uac=148436CN